A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies

Inclusion Criteria

• •Non-hematologic malignancy that has progressed or no standard therapy is known
• •Four weeks from last chemotherapy or two weeks from last non-cytotoxic therapy
• •Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
• •No more than 3 prior chemotherapy regimens in advanced/metastatic setting
• •Absolute neutrophil count \>=1,500/mm3 and platelets \>=100,000/mm3
• •Bilirubin \<=1.5 x Upper Limit of Normal (ULN), Aspartate aminotransferase \<=2.5 x ULN
• •Serum creatinine \<=1.5 x ULN
• •Men and women \>=18 years
• •Women of Child Bearing Potential (WOCBP) must use adequate method of contraception throughout and up to 4 weeks after the study